


The first DES to provide the synergy of Biodegradable Polymer with microporous surface protected with thermal insulation packing and electronic monitoring device for high quality and optimal performance



Setting New Standards of Quality Control

- At temperature beyond 8 to 25°C, Sirolimus develops oxidative degradation or Group-II impurities which may impact the potency of the drug.
- To ensure protection from various environmental conditions, Yukon Choice PC Elite is equipped with **Polystyrene Thermal Insulation Packing**.
- The thermal insulated pack is further monitored by an electronic monitoring device **TagAlert manufactured by SENSITECH USA** that have built in alarms to ensure the stent remains within the desired temperature for optimal Sirolimus potency.



Less Polymeric Load Compared to Other DES

- One million pores per cm² with average depth of 2 µm ensures optimum drug release with **1/4th of polymeric load** as compared to other DES.
- Top coat with Shellac Resin ensures better polymer drug binding with negligible polymer flaking during stent expansion.

Yukon Choice PC Elite
Sirolimus Eluting Coronary Stent System

PRODUCT MATRIX / ORDERING INFORMATION*

Stent Diameter Ø [mm]	Stent length [mm] & Article number							
	8	12	16	18	21	24	28	32
Ø 2.00	YCET2008	YCET2012	YCET2016	YCET2018	YCET2021	YCET2024	YCET2028	YCET2032
Ø 2.25	YCET2208	YCET2212	YCET2216	YCET2218	YCET2221	YCET2224	YCET2228	YCET2232
Ø 2.50	YCET2508	YCET2512	YCET2516	YCET2518	YCET2521	YCET2524	YCET2528	YCET2532

Stent Diameter Ø [mm]	Stent length [mm] & Article number									
	8	12	16	18	21	24	28	32	36	40
Ø 2.75	YCET2708	YCET2712	YCET2716	YCET2718	YCET2721	YCET2724	YCET2728	YCET2732	YCET2736	YCET2740
Ø 3.00	YCET3008	YCET3012	YCET3016	YCET3018	YCET3021	YCET3024	YCET3028	YCET3032	YCET3036	YCET3040
Ø 3.50	YCET3508	YCET3512	YCET3516	YCET3518	YCET3521	YCET3524	YCET3528	YCET3532	YCET3536	YCET3540
Ø 4.00	YCET4008	YCET4012	YCET4016	YCET4018	YCET4021	YCET4024	YCET4028	YCET4032	YCET4036	YCET4040

* Please contact our Customer Care for available sizes

COMPLIANCE CHART

Balloon Ø [mm]	Inflation pressure (bar / 10 ⁵ Pa)														
				NP							RBP				
	6	7	8		9	10	11	12	13	14		15	16	17	18
Ø 2.00	1.90	1.94	1.97	2.00	2.03	2.07	2.10	2.13	2.17	2.20	2.23	2.27	2.35	2.38	2.41
Ø 2.25	2.15	2.18	2.21	2.25	2.28	2.32	2.35	2.38	2.42	2.45	2.49	2.52	2.55	2.59	2.62
Ø 2.50	2.40	2.43	2.47	2.50	2.54	2.57	2.60	2.64	2.67	2.71	2.74	2.77	2.81	2.84	2.88
Ø 2.75	2.65	2.68	2.72	2.75	2.78	2.82	2.85	2.88	2.92	2.95	2.98	3.01	3.28	3.31	3.34
Ø 3.00	2.89	2.93	2.97	3.00	3.04	3.08	3.12	3.15	3.19	3.23	3.26	3.30	3.34	3.37	3.41
Ø 3.50	3.37	3.42	3.46	3.50	3.54	3.58	3.63	3.67	3.71	3.75	3.79	3.84	3.88	3.92	3.96
Ø 4.00	3.85	3.90	3.95	4.00	4.05	4.10	4.16	4.21	4.26	4.31	4.36	4.41	4.46	4.51	4.56

TECHNICAL DATA

Medical Stainless Steel, 316 LVM, Surface Containing Micro-Pores

Crossing Profile (Ø 2.5 mm)	0.035" / 0.89 mm	Entry Profile	0.016" / 0.41 mm
Strut Thickness (Ø 2.5 mm)	0.0034" / 87 µm	Proximal Shaft Diameter	1.9 F
Metallic Surface Area	16 - 18%	Distal Shaft Diameter	2.7 F
No Foreshortening		Recommended Guide Wire	0.014"
Balloon Marker Material	Platinum / Iridium	Guiding Catheter	min. 5 F



Manufactured By:
Translumina Therapeutics LLP
Plot No. 12, Pharmacy, Selaqui, Dehradun 248 197
(Uttarakhand) India
Drug Manufacturing License No. 12/UA/SC/P-2016

Registered Office:
Translumina Therapeutics LLP
Ground Floor, Metro Tower, LSC MOR Land,
New Rajinder Nagar, New Delhi 110 060 - India

Under Technological Collaboration With:
Translumina GmbH
Neue Rottenburger Strasse 50,
D-72379 Hechingen, Germany



CMC Medical Devices & Drugs S.L.
c/HoracioLengo Nº 18, CP 29006, Malaga - Spain
Tel: +34951214054 Fax: +34952330100
Email: mmateos@cmcmedicaldevices.com
www.cmcmedicaldevices.com

Customer Care No.: 011-28742874
Email: info@translumina.in
Visit www.translumina.in for more details.

Yukon Choice PC Elite is a registered trademark of
Translumina Therapeutics LLP

Please refer to the **Instructions for Use** supplied with these devices for
indications, contraindications, adverse effects, suggested procedures,
warnings and precautions.

Doc.Ref.No.YCET-BC Issue01, Revision 06



Yukon Choice PC Elite
Sirolimus Eluting Coronary Stent System

Lasting bonds warm the heart.

Yukon Choice **PC Elite**

Sirolimus Eluting Coronary Stent System

World's Longest Studied Drug Eluting Stent

► **2004**  CATHETERIZATION
CARDIOVASCULAR INTERVENTIONS
89:367-374 (2017)

At 2 years, microporous surface was found to be equally safe as compared to electropolished surface. Rough surfaces showed lesser restenosis rates.

► **2008**  **Biomaterials**

In Pre-clinical trial, it was seen that **Yukon Choice PC** with microporous surface reduced the amount of polymeric load to 1/4th and is assured with consistent kinetics & low inflammation.

► **2012**  **European Heart Journal**

At four years follow up, **Yukon Choice PC** shows reduction of risk by 50% in Definite Stent Thrombosis & by 78% in Very Late stent thrombosis as compared to the first generation DES with similar efficacy.

► **2013**  **International Journal of CARDIOLOGY**

At four years follow up, **Yukon Choice PC** demonstrated reduced rates in stent thrombosis in patients with diabetes mellitus as compared to durable polymer.

► **2011**  **JACC**
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

At 3 years, **Yukon Choice PC** proved equivalence to Xience in terms of Late loss, TLR and Primary Composite MACE.

► **2014**  **EuroIntervention**

Yukon Choice PC showed equivalent efficacy & better safety in terms of stent thrombosis compared to Xience & Cypher at 5 years follow up.

► **2018**  **ESC**
European Society of Cardiology

Yukon Choice PC is recommended by ESC guidelines 2018 on the basis of large randomized trials where primary end points were achieved.



► **2018**  **Circulation**
JOURNAL OF THE AMERICAN HEART ASSOCIATION

At 10 years, **Yukon Choice PC** showed equivalence in terms of MACE rate, Mortality and TLR rate compared to Xience and a superiority over Cypher for the same outcomes.

Yukon Choice PC showed the lowest rate of definite or probable stent thrombosis with a significant risk reduction than the Cypher stent (50% reduction) and a numerically lower rate as than the 'Xience' stent (29% reduction).

